Why is CBD so popular? Follow the dates

Saturday morning, the supplement aisle. A bottle of CBD oil sits between the magnesium and the fish oil, and somebody asks the obvious thing: how did this end up here, next to the vitamins? The short answer has dates in it, not adjectives.

Two lab results, fifty years apart

1940, Minnesota wild hemp

The molecule had a structure on paper long before it had a shelf. In 1940, Roger Adams and his colleagues published the structure of cannabidiol, isolated from an extract of Minnesota wild hemp [1]. Read that slowly, because the claim is narrower than it looks. A structure paper describes how a molecule is put together, atom by atom. It says nothing about what happens inside a person. This was chemistry, carried out in a decade with no supplement aisle, no product reviews and no CBD category to sell into. Which is exactly why the date is worth keeping. When someone calls CBD a new invention, the first written description of the compound is older than most of the food labels in your kitchen. And when someone calls that same paper proof of something, it is worth remembering which field it came from. Chemistry, 1940, checkable.

1990, a receptor described

The second fixed point is 1990. Matsuda and colleagues published the structure of a cannabinoid receptor together with the functional expression of the cloned cDNA [2]. Translated: a receptor was described at molecular level, and the gene coding for it was expressed in a laboratory system so it could be studied directly. Before that, the word cannabinoids did a narrower job. It grouped compounds by where they came from, a botanical family and a shared plant origin, and that was the definition. After 1990, the same word sat beside a described receptor on the human side of the biology. That is why this paper turns up so often in popularity stories, and it deserves to be read as what it is: molecular biology, 1990 [2]. Fifty years between the two results. Neither was written to sell a bottle.

The decade the rules moved

2013 to 2019, two regions

The third fixed point is not a single day. It runs across the 2010s, and what it changes is the question itself. Somewhere between roughly 2013 and 2019, the practical rules around hemp and hemp extracts shifted in Europe and in the United States. That is the part that explains scale. Not enthusiasm, not a breakthrough. Rules about what could be grown, imported, extracted and put on a shelf. In the United States, 2018 brought a widening of the federal rules on hemp cultivation. More legal acreage on one side of the Atlantic changes what raw material exists, and raw material is where extract comes from. Supply widens, extract widens, products follow. Ask anyone who was sourcing hemp extract in 2013 and then again in 2019: the difference was not the molecule. The chemistry from 1940 [1] had not moved a millimetre. The filing cabinets had.

Novel foods and 15 May 1997

Europe reached the same shelf by another route. In the EU, extracts containing cannabinoids are classified as novel foods. The criterion behind that classification is itself a date: no significant record of human consumption within the EU before 15 May 1997. Where such a record is absent, authorisation is required before the product can be sold. So the European question became an application question with a cut-off date at its centre, while the American question ran largely through cultivation. One decade, two mechanisms, one visible result in shops across the continent. This is the least glamorous section of the whole story and the most useful one. Popularity followed availability. Availability followed rules. Everything else, including the confident marketing that arrived with it, came afterwards.

Why the shelf filled first

No single thing flipped this category. Not one study, not one product launch, not one famous endorsement. Worth saying plainly, because popularity stories usually want a hero moment, and this one does not have one.

Evidence runs on a different clock. A body of human data needs funding before anything else exists. Then trial design, which is slow, technical and argued over. Then recruitment, which means finding and enrolling real participants. Then time, because follow-up cannot be compressed. Four inputs, none of them influenced by how many bottles a retailer stocks.

Market access kept its own schedule. In Europe, CBD entered through the food supplement category, and food supplement law does not require efficacy trials before a product goes on sale. That single fact explains most of the mismatch people notice. The paperwork clock and the clinical clock were never obliged to run in step. The novel food route adds an authorisation step on top, and that step governs market access, with the 15 May 1997 consumption criterion as its test.

So you end up with a category that is widely available while the human evidence is still being assembled. The two things sit side by side without contradicting each other. Both papers at the base of this story are laboratory results: a chemical structure in 1940 [1] and a receptor description in 1990 [2]. Dated, citable, and a different kind of document from a clinical answer.

Which makes the honest reply to why CBD is everywhere fairly dull. Rules moved. Supply followed. Retail followed supply. Interest measures how many people are looking, not what has been measured in them.

The record, in one view

Since 2014, from the inside

Cibdol was founded in Switzerland and has worked with cannabinoids since 2014. That puts the company in place before the regulatory turn had run its course and before CBD became a mainstream retail category, which is a particular vantage point. From it, you mostly watch language arrive. Several waves of very confident talk have passed through this category since 2014. Each one sounded permanent. Each one receded. What stayed constant through all of them was duller and more useful: the batch, the analysis, the declared content on the label.

Swiss habits help here. Precision is not a mood, it is how a certificate gets filled in. So the internal answer to why CBD is popular is not a marketing narrative at all. It is a folder of dates: when the rules changed, when supply widened, when the category still needed explaining and when it stopped needing that. Working with cannabinoids since 2014 teaches you which parts of a bottle can be verified, and those parts are short and specific:

• The declared cannabinoid content, per bottle and per millilitre, because that is the figure an independent analysis can either confirm or contradict.
• The batch number, because a certificate only means something when it matches the bottle in your hand.
• The extract type, full spectrum or isolate, since full spectrum means a broader cannabinoid profile from the same plant material rather than one isolated compound.
• The category the product is sold under, since food supplement and novel food carry different paperwork in Europe.
• The THC figure, because it is a measured number held within legal limits, and legal limits are written down rather than implied.

Seven questions worth asking

1. Which year is the claim leaning on? If the answer is 1940, that is the Adams paper describing the structure of cannabidiol from an extract of Minnesota wild hemp [1]. A structure. How the molecule is built, and nothing beyond that.
2. What was actually measured? Matsuda and colleagues in 1990 described a receptor structure and the functional expression of the cloned cDNA [2]. Laboratory molecular biology, done in a controlled system, and worth naming as such when someone quotes it loosely.
3. Is the word being used in its older sense? Before 1990, cannabinoids named a group of plant compounds by botanical family and shared origin. Older texts using that definition mean something narrower than a modern reader assumes.
4. Which region, and which rule? The United States widened federal hemp cultivation rules in 2018. The European route runs through novel food classification instead. Two mechanisms with two different logics, and mixing them makes the availability story unreadable.
5. Does the 15 May 1997 criterion apply? For cannabinoid-containing extracts in the EU, the absence of a significant record of human consumption before that date brings an authorisation requirement ahead of sale. It is a date test, not a quality test.
6. Under which category is the product sold? In Europe, CBD entered through food supplements, and food supplement law involves no efficacy trials before sale. So the shelf date and the data date are separate lines, and reading them as one line is where confusion starts.
7. Where is the batch analysis? Ask for the report, check that the number on it matches the bottle, then read the declared cannabinoid content against what the analysis found. Of everything in this story, that is the part you can verify yourself today.